Donate
News + Publications
Careers
Donate
Contact
Back
Who
We Are
Board of Directors + Governance
Our Leadership
Our Team
Our Partners
Our Benefactors
Our History
Our Financials
Health Impact Reports
Our
Programs
All Programs
Accelerating Medicines Partnership® (AMP®)
Accelerating COVID-19 Therapeutic Interventions & Vaccines (ACTIV)
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Biomarkers Consortium
GeneConvene Global Collaborative
Azithromycin Prevention in Labor Use Study (A-PLUS)
Master Protocol for Treatment of Non-Small Cell Lung Cancer (Lung-MAP)
Partnership For Accelerating Cancer Therapies (PACT)
Edmond J. Safra Family Lodge
All of Us Scholars Program
Education & Training Programs
Fighting
Diseases
All Disease
Cancer
Cardiovascular
Infectious Diseases
Inflammation + Immunology
Metabolic Disorders
Neuroscience
Rare Diseases
Women’s Health
Powering
Science
Team Science Day 2024
FNIH Awards Ceremony
The Lurie Prize in Biomedical Sciences
Trailblazer Prize for Physician-Scientists
Charles A. Sanders, MD Partnership Award
The Kovler Prize for Trust in Life Science Journalism
The Deeda Blair Research Initiative for Disorders of the Brain
Research Support
Fellowships & Training
Lectures
Patient
Voices
Patient and Family Resources
Donate
Partner With Us
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
